Dr. Reddy's Laboratories' Miryalaguda API facility in India underwent a US FDA GMP inspection (May 19-24, 2025), resulting in a Form 483 with two observations. The company plans to address them promptly.
Adani Ports May 2025 Performance Surge
RateGain & Cloudbeds Unite AI for Hotel Growth
Go Digit Q1 Profit Jumps 37% YoY
India Eases Clean-Air Rules for Plants
Atal Pension Yojana Hits 8 Cr Mark
Jash Expands with New Plant Deal
Nifty, Sensex Slip on Bank Woes
News that matters the most ⚡